The Importance of Ligand-Receptor Conformational Pairs in Stabilization: Spotlight on the N/OFQ G Protein-Coupled Receptor

Structure

Volumn 23, Issue 12, 2015, Pages 2291-2299

  Miller, Rebecca L ^a   Thompson, Aaron A ^a   Trapella, Claudio ^b   Guerrini, Remo ^b   Malfacini, Davide ^b   Patel, Nilkanth ^c   Han, Gye Won ^c   Cherezov, Vadim ^c   Caló, Girolamo ^b   Katritch, Vsevolod ^c   Stevens, Raymond C ^a,c  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

BRET; G protein coupled receptor; GPCR; lipidic cubic phase; membrane protein; N OFQ; Nociceptin orphanin FQ peptide receptor; NOP; opioid receptor; ORL 1; receptor ligand conformational pair

Indexed keywords

1 (1 CYCLOOCTYLMETHYL 3 HYDROXYMETHYL 4 PIPERIDYL) 3 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; LIGAND; N (4 AMINO 2 METHYL 6 QUINOLINYL) 2 (4 ETHYLPHENOXYMETHYL)BENZAMIDE; NOCICEPTIN RECEPTOR; OPIATE RECEPTOR; CIS-1-METHYL-7-((4-(2,6-DICHLOROPHENYL)PIPERIDIN-1-YL)METHYL)-6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTEN-5-OL; CYCLOHEPTANE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN BINDING;

ANTAGONIST POTENCY; ARTICLE; BINDING AFFINITY; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CARBOXY TERMINAL SEQUENCE; CRYSTAL STRUCTURE; CRYSTALLIZATION; EMBRYO; HUMAN; HUMAN CELL; HYDROGEN BOND; LIGAND BINDING; LIPOPHILICITY; MOLECULAR DOCKING; PARTITION COEFFICIENT; PRIORITY JOURNAL; PROTEIN CONFORMATION; THERMOSTABILITY; AMINO ACID SEQUENCE; BINDING SITE; CHEMISTRY; HEK293 CELL LINE; METABOLISM; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; BINDING SITES; CYCLOHEPTANES; HEK293 CELLS; HUMANS; LIGANDS; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; PIPERIDINES; PROTEIN BINDING; RECEPTORS, OPIOID;

EID: 84949661467     PISSN: 09692126     EISSN: 18784186     Source Type: Journal    
DOI: 10.1016/j.str.2015.07.024     Document Type: Article

References (48)

1. R. Abagyan, M. Totrov, and D. Kuznetsov ICM - a new method for protein modeling and design - applications to docking and structure prediction from the distorted native conformation J. Comput. Chem. 15 1994 488 506
2. R.A. Abagyan, A. Orry, E. Raush, L. Budagyan, and M. Totrov ICM Manual 2009 MolSoft LLC
3. P.D. Adams, P.V. Afonine, G. Bunkoczi, V.B. Chen, I.W. Davis, N. Echols, J.J. Headd, L.W. Hung, G.J. Kapral, R.W. Grosse-Kunstleve, and et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr. D Biol. Crystallogr. 66 2010 213 221
4. A.I. Alexandrov, M. Mileni, E.Y. Chien, M.A. Hanson, and R.C. Stevens Microscale fluorescent thermal stability assay for membrane proteins Structure 16 2008 351 359
5. C. Alt, J.S. Lam, M.T. Harrison, K.M. Kershaw, S. Samuelsson, L. Toll, and A. D'Andrea Nociceptin/orphanin FQ inhibition with SB612111 ameliorates dextran sodium sulfate-induced colitis Eur. J. Pharmacol. 683 2012 285 293
6. M. Audet, and M. Bouvier Restructuring G-protein-coupled receptor activation Cell 151 2012 14 23
7. J. Ballesteros, and H. Weinstein Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors Methods Neurosci. 25 1995 366 428
8. A. Bock, B. Chirinda, F. Krebs, R. Messerer, J. Batz, M. Muth, C. Dallanoce, D. Klingenthal, C. Trankle, C. Hoffmann, and et al. Dynamic ligand binding dictates partial agonism at a G protein-coupled receptor Nat. Chem. Biol. 10 2014 18 20
9. B.D. Bursulaya, M. Totrov, R. Abagyan, and C.L. Brooks 3rd Comparative study of several algorithms for flexible ligand docking J. Comput. Aided Mol. Des. 17 2003 755 763
10. M. Caffrey, and V. Cherezov Crystallizing membrane proteins using lipidic mesophases Nat. Protoc. 4 2009 706 731
11. V.B. Chen, W.B. Arendall 3rd, J.J. Headd, D.A. Keedy, R.M. Immormino, G.J. Kapral, L.W. Murray, J.S. Richardson, and D.C. Richardson MolProbity: all-atom structure validation for macromolecular crystallography Acta Crystallogr. D Biol. Crystallogr. 66 2010 12 21
12. V. Cherezov, A. Peddi, L. Muthusubramaniam, Y.F. Zheng, and M. Caffrey A robotic system for crystallizing membrane and soluble proteins in lipidic mesophases Acta Crystallogr. D Biol. Crystallogr. 60 2004 1795 1807
13. P. Emsley, B. Lohkamp, W.G. Scott, and K. Cowtan Features and development of Coot Acta Crystallogr. D Biol. Crystallogr. 66 2010 486 501
14. C. Fischetti, V. Camarda, A. Rizzi, M. Pela, C. Trapella, R. Guerrini, J. McDonald, D.G. Lambert, S. Salvadori, D. Regoli, and et al. Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24 Eur. J. Pharmacol. 614 2009 50 57
15. E.C. Gavioli, and G. Calo Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs Pharmacol. Ther. 140 2013 10 25
16. Y. Goto, S. Arai-Otsuki, Y. Tachibana, D. Ichikawa, S. Ozaki, H. Takahashi, Y. Iwasawa, O. Okamoto, S. Okuda, H. Ohta, and et al. Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity J. Med. Chem. 49 2006 847 849
17. R. Guerrini, G. Calo, A. Rizzi, C. Bianchi, L.H. Lazarus, S. Salvadori, P.A. Temussi, and D. Regoli Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide J. Med. Chem. 40 1997 1789 1793
18. T. Halgren Merck molecular force field I-V J. Comp. Chem. 17 1995 490 641
19. V. Katritch, G. Fenalti, E.E. Abola, B.L. Roth, V. Cherezov, and R.C. Stevens Allosteric sodium in class A GPCR signaling Trends Biochem. Sci. 39 2014 233 244
20. H. Kawamoto, S. Ozaki, Y. Itoh, M. Miyaji, S. Arai, H. Nakashima, T. Kato, H. Ohta, and Y. Iwasawa Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397) J. Med. Chem. 42 1999 5061 5063
21. D.G. Lambert The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential Nat. Rev. Drug Discov. 7 2008 694 710
22. A.P. Lin, and M.C. Ko The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability ACS Chem. Neurosci. 4 2013 214 224
23. C.A. Lipinski Lead- and drug-like compounds: the rule-of-five revolution Drug Discov. Today Technol. 1 2004 337 341
24. 19F-NMR Science 335 2012 1106 1110
25. D. Malfacini, C. Ambrosio, M.C. Gro, M. Sbraccia, C. Trapella, R. Guerrini, R. Broide, J. Francis, M. Bonora, P. Pinton, and et al. Pharmacological profile of nociceptin/orphanin FQ receptors interacting with G-proteins and β-arrestins 2 PLoS One 10 2015 e0132865
26. A. Manglik, T.H. Kim, M. Masureel, C. Altenbach, Z. Yang, D. Hilger, M.T. Lerch, T.S. Kobilka, F.S. Thian, W.L. Hubbell, and et al. Structural insights into the dynamic process of beta2-adrenergic receptor signaling Cell 161 2015 1101 1111
27. M. Marti, F. Mela, M. Budri, M. Volta, D. Malfacini, S. Molinari, N.T. Zaveri, S. Ronzoni, P. Petrillo, G. Calo, and et al. Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111 Br. J. Pharmacol. 168 2013 863 879
28. A.J. McCoy Solving structures of protein complexes by molecular replacement with Phaser Acta Crystallogr. D Biol. Crystallogr. 63 2007 32 41
29. J. McDonald, T.A. Barnes, G. Calo, R. Guerrini, D.J. Rowbotham, and D.G. Lambert Effects of [(pF)Phe(4)]nociceptin/orphanin FQ-(1-13)NH(2) on GTPgamma(35)S binding and cAMP formation in Chinese hamster ovary cells expressing the human nociceptin/orphanin FQ receptor Eur. J. Pharmacol. 443 2002 7 12
30. J. McDonald, G. Calo, R. Guerrini, and D.G. Lambert UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPgamma(35)S binding studies Naunyn Schmiedebergs Arch. Pharmacol. 367 2003 183 187
31. P. Molinari, I. Casella, and T. Costa Functional complementation of high-efficiency resonance energy transfer: a new tool for the study of protein binding interactions in living cells Biochem. J. 409 2008 251 261
32. C. Mollereau, M. Parmentier, P. Mailleux, J.L. Butour, C. Moisand, P. Chalon, D. Caput, G. Vassart, and J.C. Meunier ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization FEBS Lett. 341 1994 33 38
33. L. Mouledous, C.M. Topham, H. Mazarguil, and J.C. Meunier Direct identification of a peptide binding region in the opioid receptor-like 1 receptor by photoaffinity labeling with [Bpa(10),Tyr(14)]nociceptin J. Biol. Chem. 275 2000 29268 29274
34. C. Mustazza, and G. Bastanzio Development of nociceptin receptor (NOP) agonists and antagonists Med. Res. Rev. 31 2011 605 648
35. R. Nygaard, Y. Zou, R.O. Dror, T.J. Mildorf, D.H. Arlow, A. Manglik, A.C. Pan, C.W. Liu, J.J. Fung, M.P. Bokoch, and et al. The dynamic process of beta(2)-adrenergic receptor activation Cell 152 2013 532 542
36. M. Rask-Andersen, S. Masuram, and H.B. Schioth The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication Annu. Rev. Pharmacol. Toxicol. 54 2014 9 26
37. A. Rizzi, E.C. Gavioli, G. Marzola, B. Spagnolo, S. Zucchini, R. Ciccocioppo, C. Trapella, D. Regoli, and G. Calo Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrah ydro-5H-benzocyclohepten-5-ol]: in vivo studies J. Pharmacol. Exp. Ther. 321 2007 968 974
38. M. Schapira, M. Totrov, and R. Abagyan Prediction of the binding energy for small molecules, peptides and proteins J. Mol. Recognit. 12 1999 177 190
39. B. Spagnolo, G. Carra, M. Fantin, C. Fischetti, C. Hebbes, J. McDonald, T.A. Barnes, A. Rizzi, C. Trapella, G. Fanton, and et al. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrah ydro-5H-benzocyclohepten-5-ol]: in vitro studies J. Pharmacol. Exp. Ther. 321 2007 961 967
40. A.A. Thompson, W. Liu, E. Chun, V. Katritch, H. Wu, E. Vardy, X.P. Huang, C. Trapella, R. Guerrini, G. Calo, and et al. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic Nature 485 2012 395 399
41. M. Totrov, and R. Abagyan Flexible protein-ligand docking by global energy optimization in internal coordinates Proteins Suppl. 1 1997 215 220
42. C. Trapella, R. Guerrini, L. Piccagli, G. Calo, G. Carra, B. Spagnolo, S. Rubini, G. Fanton, C. Hebbes, J. McDonald, and et al. Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist Bioorg. Med. Chem. 14 2006 692 704
43. C. Trapella, C. Fischetti, M. Pela, I. Lazzari, R. Guerrini, G. Calo, A. Rizzi, V. Camarda, D.G. Lambert, J. McDonald, and et al. Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4′-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide Bioorg. Med. Chem. 17 2009 5080 5095
44. L. Vachon, T. Costa, and A. Herz Opioid receptor desensitization in NG 108-15 cells. Differential effects of a full and a partial agonist on the opioid-dependent GTPase Biochem. Pharmacol. 36 1987 2889 2897
45. N. Vaidehi, S. Bhattacharya, and A.B. Larsen Structure and dynamics of G-protein coupled receptors Adv. Exp. Med. Biol. 796 2014 37 54
46. M.S. Weiss Global indicators of X-ray data quality J. Appl. Crystallogr. 34 2001 130 135
47. P.F. Zaratin, G. Petrone, M. Sbacchi, M. Garnier, C. Fossati, P. Petrillo, S. Ronzoni, G.A. Giardina, and M.A. Scheideler Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111) J. Pharmacol. Exp. Ther. 308 2004 454 461
48. X. Zhang, R.C. Stevens, and F. Xu The importance of ligands for G protein-coupled receptor stability Trends Biochem. Sci. 40 2015 79 87